“Buyout firms have struck 13 so-called public-to-private deals in Britain so far this year for a total value of almost $31bn,” says Ben Dummett in The Wall Street Journal. That’s more than double the number for the whole of last year and the best performance over the same period since 2007.
Private-equity funds invest in private companies or buy out publicly listed ones. The bidding war for Wm Morrison Supermarkets has only been the most “high-profile” example of the trend. Healthcare, property and defence businesses are also being snapped up.
Why the boom? Private-equity firms have “mounds of low-cost debt to make acquisitions” thanks to low interest rates. But takeovers usually require the buyer to pay a premium, which is difficult to justify in the pricey US market.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Britain, by contrast, is cheap. Data from broker Peel Hunt shows that on a forward 12-month price/earnings basis Britain is “40% cheaper than the US market and 25% cheaper than the eurozone”, says cmcmarkets.com. “S&P 500 firms typically trade at 23 times earnings, compared with just 14 times in London.”
Britain’s quiet IPO boom
The private-equity bidding war is good for share prices. But it has also caused concern about the long-term health of the London market. If private firms delist some of Britain’s best businesses, then what will remain for ordinary investors?
Not to worry, says Simon Foy in The Daily Telegraph. As quickly as firms are going private, plenty of new ones are coming onto the market. “Since the beginning of the year, 54 companies, with a combined market value of £53bn, have floated on the London Stock Exchange”.
There is a widespread impression that the London bourse is “struggling”. That’s thanks to Deliveroo’s “high-profile flop” – shares in the food-delivery app plunged 26% after listing in March. But as Simon French of Panmure Gordon notes, “if you took an equal stake in each of the companies that have floated this year, your investment would be up by about a third in the year to date”, beating the wider FTSE All-Share’s gain of 7.8%.
Investors are often warned against having a “home bias”, says David Brenchley in The Times. Almost half of British investors told a Quilter survey that “more than 50% of their investments were in the UK…One in 12 people with more than £60,000 invested admitted to having all of their investments in UK stocks”. Investors who failed to diversify globally have paid the price over the past decade as US markets soared while the FTSE stagnated, but that trend will reverse at some point. Remember that “for a long time before the financial crisis, UK stocks beat American ones”. It’s never a good idea to put all your eggs in one basket, but a touch of home bias looks a sound strategy for now.
-
When is the “Bed & ISA” deadline? Cut-off dates for major investment platformsThe “Bed & ISA” deadline varies from provider to provider. We share a round-up of the key dates across major investment platforms
-
Spring Statement: what could Rachel Reeves say about pensions?The chancellor will deliver her Spring Statement on 26 March. We look at whether there will be any announcements on pensions that could affect savers or retirees
-
Why CEOs deserve a pay riseOpinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
-
Rolls-Royce stock jumps 15% – could it climb further?Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
-
The power of private marketsInterview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success
-
Global investors have overlooked these top tips in emerging marketsOpinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
-
King Coal has not been dethroned yet — should you buy?The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
-
It’s time to start buying Europe again, says Merryn Somerset WebbOpinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fadesFood-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
